Categories: AnalystsCannabis

Legalization delays mean added uncertainty for pot stocks, Echelon says

Now we play the waiting game.

The timeline to pot legalization in Canada has been stretched out to late summer and possibly early fall, according to a new statement from the federal government, which plans to introduce an eight-to-12 week transition period after legislation has been passed.

Intended to give industry players as well as provincial and territorial governments enough time to set up shop, the lag won’t hurt plans in the long run, says Echelon Wealth, but stock prices in the ever-fluctuating sector are another story.

Yesterday, Health Minister Ginetter Petitpas Taylor revealed that the passing of Bill C-45 to legalize the recreational use of marijuana — expected to gain Senate approval sometime in May or June —won’t mean that Canadians can right away rush to their nearest dispensary and/or provincial outlet. Instead, the government aims to put in place a two-to- three month buffer after legalization.

“There is going to be a transition period because we have to ensure that provinces and territories have the capacity to get the products in their shops,” Ms. Petitpas Taylor told reporters after appearing in front of a special meeting of the Senate. “They’ll need a period of time of up to eight to 12 weeks in order to properly ensure that their retail sales will be prepared.”

That could mean August or even September before things are up and running, which won’t matter much except, potentially, to the markets, which seem to yo-yo up and down on little or no substantive developments in the sector.

That’s the conclusion of analysts Russell Stanley and Andrew Semple of Echelon Wealth, who today issued a note on the federal government’s news, saying the government’s ongoing lack of clarity on a start date may be bewildering, but so are shifting valuations for weed stocks.

“We have been very conservative on our C2018 estimates, and our valuations for our formal coverage universe are based on estimates for C2019, so we see no need to make revisions at this point,” say the analysts.

“Ultimately, a delay (if there is one) of eight to twelve weeks should not matter to investors, but we concede that the cannabis space is extremely sentiment-driven right now, and would not be surprised if share prices reflect more uncertainty with respect to the timing legalization,” they write.

Marijuana stocks had a dream run in 2017 with the market cooling off in January. But much uncertainty still hovers around the yet-to- be-realized market, as companies continue to jockey for position ahead of legalization. Still, billions of dollars have been poured into Canada’s pot co’s, as investors try to pick the winners.

Yet, the extra wait time could help a number of companies sort out their operations ahead of the start date. On the shifting timeline, Canopy Growth Corp CEO Bruce Linton said, ”In my mind, I’ve been thinking August 1. So if it’s July 10 or 18, I really don’t care,” he told the Globe and Mail. “It’s going to be better if it’s in the summer because people are on vacation. But, other than that, every minute that we have longer just allows us to have more assets available and to negotiate better deals.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

3 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

4 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

5 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

1 day ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

1 day ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

2 days ago